Table 5 Virological and immunological parameters according to immunocompromised vs non-immunocompromised status
Immunocompromised | Non-immunocompromised | Total | P-value | |
|---|---|---|---|---|
Total | 593 | 83 | 676 | |
Gender | ||||
Cis-male | 549 (92.6%) | 73 (88%) | 622 (92%) | |
Cis-female | 42 (7.1%) | 10 (12%) | 52 (7%) | chi2 P = 0.25 |
Trans-female | 2 (0.3%) | 0 (0%) | 2 (1%) | |
Mean age (years) Range | 41 16–75 | 74 39–88 | 43 16–88 | MW P < 0.0001* |
Race | ||||
White-Caucasian | 441 (75.5%) | 44 (53%) | 489 (72%) | |
Black-African | 112 (19%) | 23 (28%) | 135 (20%) | chi2 P < 0.0001* |
Asian | 32 (5%) | 4 (5%) | 36 (5%) | |
Other | 8 (0.5) | 12 (14%) | 20 (3%) | |
Skin sites of KS lesions | ||||
Localised | 157 (26%) | 51 (52%) | 208 (31%) | |
Regional | 76 (13%) | 5 (6%) | 81 (12%) | chi2 P < 0.0001* |
Disseminated | 332 (56%) | 25 (20%) | 357 (53%) | |
None | 28 (5%) | 2 (2%) | 30 (4%) | |
Histological grades of KS | ||||
Patch | 93 (16%) | 3 (4%) | 96 (14%) | |
Plaque | 269 (45%) | 24 (29%) | 293 (43%) | chi2 P < 0.0001* |
Nodular | 183 (31%) | 48 (57%) | 231 (34%) | |
Not otherwise specified | 48 (8%) | 8 (10%) | 56 (8%) | |
Disease extent | chi2 P = 0.0012* | |||
Disease limited to Skin | 440 (74%) | 75 (90%) | 515 (76%) | |
Advanced KS any site* | 153 (26%) | 8 (10%) | 161 (24%) | |
Sites of advanced KS involvement at diagnosis* | ||||
Gastro-intestinal | 53 (9%) | 3 (4%) | 56 (8%) | chi2 P = 0.09 |
Pulmonary | 66 (11%) | 4 (5%) | 70 (10%) | chi2 P = 0.07 |
Other Viscera | 102 (17%) | 8 (10%) | 110 (16%) | chi2 P = 0.08 |
Extensive oral involvement | 84 (14%) | 0 (0%) | 84 (12%) | FE P < 0.0001* |
Characteristics of advanced KS at diagnosis | ||||
Tumour Associated Odema | 93 (16%) | 17 (20%) | 110 (16%) | chi2 P = 0.26 |
Tumour Ulceration | 64 (11%) | 11 (13%) | 75 (11%) | chi2 P = 0.50 |